These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33416171)

  • 1. Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
    Brum MCM; Dos Santos Guimaraes I; Ferreira LB; Rangel LBA; Maia RC; Nestal De Moraes G; Gimba ERP
    Oncol Rep; 2021 Feb; 45(2):652-664. PubMed ID: 33416171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
    Nakamura KD; Tilli TM; Wanderley JL; Palumbo A; Mattos RM; Ferreira AC; Klumb CE; Nasciutti LE; Gimba ER
    Tumour Biol; 2016 Feb; 37(2):2655-63. PubMed ID: 26404131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin-c splicing isoform contributes to ovarian cancer progression.
    Tilli TM; Franco VF; Robbs BK; Wanderley JL; da Silva FR; de Mello KD; Viola JP; Weber GF; Gimba ER
    Mol Cancer Res; 2011 Mar; 9(3):280-93. PubMed ID: 21263033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.
    Tilli TM; Bellahcène A; Castronovo V; Gimba ER
    BMC Cancer; 2014 Jun; 14():433. PubMed ID: 24928374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
    Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
    Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.
    Goparaju CM; Pass HI; Blasberg JD; Hirsch N; Donington JS
    J Thorac Oncol; 2010 Oct; 5(10):1516-23. PubMed ID: 20689445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
    Li S; Yi Z; Li M; Zhu Z
    J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.
    Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q
    Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line.
    Alghamian Y; Soukkarieh C; Abbady AQ; Murad H
    Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer.
    Han X; Liu D; Zhou Y; Wang L; Hou H; Chen H; Zhang L; Chen W; Li X; Zhao L
    Cell Biol Int; 2021 Jan; 45(1):227-237. PubMed ID: 33090550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of sodium butyrate and cisplatin on expression of EMT markers.
    Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
    PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial‑mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.
    Wang Y; Yang B; Zhao J; Yu X; Liu X; Zhang L; Zhang Y; Li X; Zhai Z
    Mol Med Rep; 2019 Mar; 19(3):1501-1508. PubMed ID: 30628686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin-c isoform levels are associated with SR and hnRNP differential expression in ovarian cancer cell lines.
    Marques DS; Grativol J; Alves da Silva Peres R; da Rocha Matos A; Gimba ERP
    Tumour Biol; 2017 Sep; 39(9):1010428317725442. PubMed ID: 28936921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.